- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2024–2029 · program · P01
RNA-based HIV-1 chimera vaccines encoding a trimerizing host self-protein protomer linked to a viral MPER-TM segment
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer
Kent W Mouw · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024 · program · P30
Tumor-associated macrophage reprogramming through PARP14 inhibition in muscle-invasive bladder cancer
Laurie Hollis Glimcher · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024 · award
Determining racial and ethnic disparities in receipt of novel therapies and survival for hepatocellular carcinoma
Christopher Manz · Dana-Farber Cancer Institute · funded by American Cancer Society
2024–2029 · research · R01
Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer
Kent W Mouw · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2027 · research · R21
Improving prognosis prediction and therapy selection for cutaneous squamous cell carcinomas using artificial intelligence
William Edward Lotter · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2027 · fellowship · CIHR Fellowship
Defining mechanisms contributing to cancer genome complexity
Tajinder Ubhi · Dana-Farber Cancer Institute · funded by Canadian Institutes of Health Research
2024–2026 · grant · RCRP
Targeting Merkel ST-MYCL-EP400 Complex in Merkel Cell Carcinoma
Om Basukala · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024–2026 · research · R21
MUC1-C is a target for advancing immunotherapy of non-small cell lung cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2028 · research · R01
Contribution of a novel OPN-producing CD11c+ microglial subset to AD
Harvey Cantor · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2028 · research · R01
Integrative modelling of single-cell data to elucidate the genetic architecture of complex disease
Alexander Gusev · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024 · career development · K99
Harnessing Exercise to Enhance Immunity and Boost Immunotherapy Outcomes in Patients with Lung Cancer
Dong-Woo Kang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · career development · K08
Molecular Dynamics of Glioma Formation and DNA Damage Response by Mutant IDH1
Diana Shi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2027 · grant · MRP
Identification of the Liver Microenvironment That Drives Uveal Melanoma Metastasis and Immunity
Rizwan Haq · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024–2029 · program · P01
Targeting Replication Stress and DNA Damage Response in Uterine Cancer
Panagiotis Konstantinopoulos · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2026 · grant · OT2
PROTECT (Harnessing PROTEin degradation for Advanced Childhood Tumors)
Kimberly Stegmaier · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · career development · K08
BCOR/PRC1.1 Inactivation In Splicing Factor Mutant MDS Progression
Rahul Vedula · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
High-throughput single-cell RNA sequencing of bacteria to uncover cell states involved in pathogenesis
Sahand Hormoz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · career development · K08
Identifying metabolic regulation of T cells during early childhood development
Jared H. Rowe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2026 · award
Interrogating the therapeutic potential of CDK5 in DNA Replication
Ke Cong · Dana-Farber Cancer Institute · funded by American Cancer Society
2024–2026 · career development · K99
Targeting mitochondrial vulnerabilities to drive intrinsic melanoma immunogenicity
Jiaxin Liang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
Inclusion of Diverse and Medically Underserved Populations in the Design and Implementation of the PREMMplus Patient-Facing App
Sapna Syngal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors
Joanna J Arch · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
Assessment of germline variants associated with immune-related adverse events following immune checkpoint inhibitors
Toni Choueiri · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2028 · grant · PRCRP
Harnessing ECD Cleavage of ALK for Immunotherapy Against Neuroblastoma
Rani George · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024 · career development · K08
Investigating SLC46A3 as a negative regulator of nanoparticle drug delivery
Joelle Payne Straehla · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · career development · K24
Collaborative Care to Improve Resilience and Quality of Life among Youth with Non-malignant Blood Disorders
Abby R Rosenberg · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2025 · grant · S10
High-Throughput DNA Sequencing System
Zachary T Herbert · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2028 · grant · PRCRP
Supporting Underrepresented Populations in Genomics-Based Cancer Trial Enrollment (SURGE)
Nadine Mccleary · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024–2028 · grant · OCRP
Enhancing the Antitumor Activity of Natural Killer Cells in Ovarian Cancer
Rebecca Porter · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024–2025 · research · R21
Leveraging mHealth to deliver integrated pain-CBT, opioid monitoring, and self-management support for advanced cancer patients coping with chronic pain
Desiree R Azizoddin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · career development · K08
Inflammatory Disease Associations in Clonal Hematopoiesis
Lachelle Dawn Weeks · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2025 · research · R01
Mitochondria mediated intercellular metabolic coupling in bone marrow regeneration
Jose A. Cancelas · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2029 · research · R01
Molecular mechanisms of developmental reprogramming in colorectal cancer
Nilay Sethi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2025 · grant · Standard Grant
Conference: Symposium on the Immune System of Bacteria
Philip Kranzusch · Dana-Farber Cancer Institute · funded by National Science Foundation
2024–2026 · grant · KCRP
Enhancement of Immune Checkpoint Blockade Responsiveness and Tertiary Lymphoid Structure Formation Through CD4+Tfhx13 CAR-T Cells to Achieve ccRCC Cures
Wayne Marasco · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024 · award
Building resilience among women with high-risk breast cancer
Abby Rosenberg · Dana-Farber Cancer Institute · funded by American Cancer Society
2024–2025 · grant · OT2
NexTGen - DFCI
Robbie G. Majzner · Dana-Farber Cancer Institute · funded by National Institutes of Health
2024–2027 · grant · PCRP
Dissecting the Interplay of Molecular and Spatial Architectures with Clinical States in Prostate Cancer
Eliezer Van Allen · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2024–2025 · research · R13
Symposium on the Immune System of Bacteria
Philip J Kranzusch · Dana-Farber Cancer Institute · funded by National Institutes of Health
